Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

[1]  W. Sandborn,et al.  Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry , 2012, The American Journal of Gastroenterology.

[2]  P. Rutgeerts,et al.  A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease , 2012, The American Journal of Gastroenterology.

[3]  P. Rutgeerts,et al.  943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC , 2012 .

[4]  T. Hibi,et al.  Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. , 2012, Journal of Crohn's & colitis.

[5]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[6]  P. Rutgeerts,et al.  Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[8]  P. Rutgeerts,et al.  Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial , 2011 .

[9]  P. Moayyedi,et al.  Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[10]  D. Hommes,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[11]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[12]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[13]  W. Sandborn,et al.  Adalimumab safety in global clinical trials of patients with Crohn's disease , 2009, Inflammatory bowel diseases.

[14]  H. Tilg,et al.  Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[15]  Li-Ming Shao,et al.  Meta‐analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease , 2009, Alimentary pharmacology & therapeutics.

[16]  M. Regueiro,et al.  Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.

[17]  A. Cohen,et al.  A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease , 2008 .

[18]  L. Peyrin-Biroulet,et al.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[20]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[21]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[22]  S. Nikfar,et al.  Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[23]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[24]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[25]  J. Mate,et al.  Systematic review: infliximab therapy in ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[26]  A. Akobeng,et al.  Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. , 2006, The Cochrane database of systematic reviews.

[27]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[28]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[29]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[30]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[31]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[32]  A. Innes,et al.  Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study , 2004, Alimentary pharmacology & therapeutics.

[33]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[34]  A. Akobeng,et al.  Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. , 2003, The Cochrane database of systematic reviews.

[35]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[36]  A. Forbes,et al.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial , 2003, Gut.

[37]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[38]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[39]  S. Targan,et al.  Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study , 2001, Inflammatory bowel diseases.

[40]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[41]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[42]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[43]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[44]  S. Stephens,et al.  Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. , 1997, Gut.

[45]  T. Macdonald,et al.  Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease , 1994 .

[46]  S. Stephens,et al.  Tumour necrosis factor alpha in stool as a marker of intestinal inflammation , 1992, The Lancet.

[47]  M. Savage,et al.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. , 1991, Gut.

[48]  A. Cooke,et al.  Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine , 1990, Clinical and experimental immunology.

[49]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[50]  B. Warner,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[51]  P. Moayyedi,et al.  Effi cacy of Biological Therapies in Infl ammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011 .

[52]  D. Porter,et al.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[54]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[55]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[56]  S. Nikfar,et al.  Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[57]  P. Rutgeerts,et al.  Randomized , Placebo-Controlled Trial of Certolizumab Pegol CDP 870 ) for Treatment of Crohn ’ s Disease , 2005 .

[58]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.